ArticleNature communications2025
Neutrophil-mediated delivery of hybrid cross-species nanovesicles for treatment of bacterial infections.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Single cell multi-omics guided hydrogel enables closed-loop therapy for renal osteodystrophy.Nature communications · 2026Article
- Bacterial extracellular membrane vesicles as multifunctional defense systems: Roles in immune evasion, phage interactions, and antimicrobial resistance.Molecular biology reports · 2026Review
- From Laboratory to Clinic: Translational Medicine Paradigm of Polymyxin B Nanopreparations for Overcoming Drug-Resistant Bacterial Infections.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Hybrid vesicles are increasingly employed as nanocarrier systems for drug delivery owing to their versatile functionalities. This study presents a multifunctional vesicle delivery platform, designated PMB@LNV-SyBV, which integrates anti-inflammatory lemon-derived exosomes and attenuated bacterial vesicles to deliver polymyxin B (PMB). The incorporation of exogenous cholesterol enhances the drug-loading capacity of these vesicles. Antimicrobial assays confirm that PMB@LNV-SyBV effectively targets carbapenem-resistant Gram-negative bacteria. By inheriting pathogen-associated molecular patterns from native bacteria, PMB@LNV-SyBV is efficiently recognized and internalized by neutrophils, enabling it to reach infection sites alongside neutrophil recruitment. Subsequently, the vesicles are released from neutrophils in response to inflammatory stimuli. In infection models involving Klebsiella pneumoniae-induced mouse pneumonia and K. pneumoniae/Escherichia coli-induced mouse bloodstream infections, PMB@LNV-SyBV significantly reduces bacterial load, modulates pro-inflammatory cytokine release, and increases sepsis survival rates. With its high yield and favorable biocompatibility, the multifunctional PMB@LNV-SyBV represents a promising therapeutic platform for the clinical management of carbapenem-resistant bacterial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.